Optipharm.CO.,LTD (KOSDAQ: 153710)

Market Cap	75.40B
Revenue (ttm)	19.09B
Net Income (ttm)	-2.27B
Shares Out	14.67M
EPS (ttm)	-155.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,914
Average Volume	10,396
Open	5,200.00
Previous Close	5,250.00
Day's Range	5,060.00 - 5,240.00
52-Week Range	4,400.00 - 7,640.00
Beta	0.62
RSI	67.81
Earnings Date	n/a

About Optipharm.CO.,LTD

Optipharm.CO.,LTD operates as a biomedical solution provider in South Korea. It also engages in animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, xenotransplantation, and other optipharm products, as well as veterinary drug for feed additives and laboratory animal Medipig business. The company was formerly known as Optiparm Solution Co., Ltd. and changed its name to Optipharm.CO.,LTD in 2012. Optipharm.CO.,LTD was founded in 2000 and is based in Cheongju, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 153710

Financial Performance

In 2023, Optipharm.CO.,LTD's revenue was 17.37 billion, an increase of 8.52% compared to the previous year's 16.01 billion. Losses were -2.44 billion, 19.2% more than in 2022.